As cellular response to ruxolitinib may lead to compensatory activation of ERK activity, combination of the more downstream inhibitors of MEK and BCL-2 proteins could augment the ability of JAK2 inhibitors to induce apoptosis in MPN-driving cells, with the caveat of the challenges of a triple combination therapy. Here, MAPK1 is linked to myeloproliferative disorder.